secwatch.observer — SEC 8-K summary
======================================

Issuer:     DEXCOM INC (DXCM)
CIK:        0001093557
Form:       8-K
Filed at:   2025-07-30T23:59:59+00:00
Accession:  0001093557-25-000241
Event type: earnings
Sentiment:  positive
Materiality: 0.88
Item codes: 2.02, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Dexcom Q2 revenue $1.157B (+15% YoY); raises FY25 revenue guidance; CEO Sayer to retire, Jake Leach named CEO
--------------------------------------------------------------------------------

- Revenue $1.157B (+15% YoY); GAAP EPS $0.45, non-GAAP EPS $0.48.
- Raises FY25 revenue guidance to $4.600-4.625B (14-15% growth); margins reiterated.
- CEO Kevin Sayer to retire Jan 1, 2026; becomes Executive Chairman. COO Jake Leach promoted to CEO and Board.
- FDA clearance for Dexcom G7 15 Day CGM System received in Q2.
- U.S. revenue +15%, international +16% reported (+14% organic).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1093557/000109355725000241/0001093557-25-000241-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1093557/000109355725000241/dxcm-20250725.htm
  HTML page:      https://secwatch.observer/filing/0001093557-25-000241

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer